IRIS
GENTILE, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 640
EU - Europa 629
NA - Nord America 598
AF - Africa 9
Totale 1.876
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 598
CN - Cina 455
IT - Italia 441
SG - Singapore 161
FI - Finlandia 68
AT - Austria 36
DE - Germania 27
KR - Corea 15
NL - Olanda 15
CZ - Repubblica Ceca 11
GB - Regno Unito 11
FR - Francia 7
SN - Senegal 7
UA - Ucraina 6
HK - Hong Kong 3
ET - Etiopia 2
JP - Giappone 2
RO - Romania 2
ES - Italia 1
HU - Ungheria 1
IE - Irlanda 1
IN - India 1
MO - Macao, regione amministrativa speciale della Cina 1
SA - Arabia Saudita 1
SE - Svezia 1
SI - Slovenia 1
TW - Taiwan 1
Totale 1.876
Salva come PNG Salva come JPEG
Città #
Florence 259
Shanghai 205
Singapore 82
Boardman 79
Ashburn 68
Ogden 68
Helsinki 56
Sesto Fiorentino 47
Noto 45
Vienna 32
Guangzhou 26
Wuhan 25
New York 23
Chandler 19
Washington 19
Beijing 17
Seoul 15
Naaldwijk 14
Rome 13
Lappeenranta 12
Los Angeles 11
Jinhua 9
Rende 9
Dakar 7
Yiwu 7
Seattle 6
Wuxi 6
Jiaxing 5
Kilburn 5
Chicago 4
Cosenza 4
Naples 4
Zibo 4
Brooklyn 3
Dalian 3
Falkenstein 3
Genoa 3
Lawrence 3
Milan 3
Palmi 3
Paris 3
Roxbury 3
Sassari 3
Addis Ababa 2
Ann Arbor 2
Bari 2
Bologna 2
Borgomanero 2
Bucharest 2
Gualdo Tadino 2
Heze 2
Hong Kong 2
Jining 2
London 2
Mestre 2
Miami 2
Nantong 2
Paola 2
Pomigliano d'Arco 2
Romainville 2
Santa Clara 2
Shenzhen 2
Tokyo 2
West Jordan 2
Bremen 1
Catania 1
Central 1
Chizhou 1
Cirò Marina 1
Cologne 1
Debrecen 1
Des Moines 1
Dipignano 1
Dublin 1
Forest City 1
Foshan 1
Frankfurt am Main 1
Fuzhou 1
Hamm 1
Hangzhou 1
Inglewood 1
Kaohsiung City 1
Lianyun 1
Ljubljana 1
Macao 1
Madrid 1
Mountain View 1
Nanjing 1
Ningbo 1
Qingdao 1
Riyadh 1
San Calogero 1
San Francisco 1
San Mateo 1
Santa Barbara 1
Serra San Bruno 1
Shaoxing 1
Taizhou 1
Tiantai Chengguanzhen 1
Udine 1
Totale 1.313
Salva come PNG Salva come JPEG
Nome #
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 75
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 40
A novel phage display based platform for exosome diversity characterization 28
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 28
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 26
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 26
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 25
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 25
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 24
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 24
Iron chelation therapy 23
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 22
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 22
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 22
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 22
Teclistamab-cqyv in multiple myeloma 22
Elotuzumab in multiple myeloma 21
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 20
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 20
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 20
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 20
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 20
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 20
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 20
Myelodysplastic syndromes with ring sideroblasts 19
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 19
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 19
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 19
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 19
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 19
Belantamab mafodotin in multiple myeloma 19
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 18
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 18
Cerebral pheohyphomycosis due to curvularia species 17
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 17
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 17
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 17
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 17
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 17
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 16
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 16
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 16
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 15
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 15
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 14
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 14
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 14
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 14
Acalabrutinib in chronic lymphocytic leukemia 14
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 14
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 14
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity 14
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma 14
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 14
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 13
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 13
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. 13
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 13
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. 13
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 13
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 12
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 12
Ivosidenib in acute myeloid leukemia 12
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 12
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 12
Editorial: Lymphoid cells and tumor microenvironment: a functional crosstalk 12
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 12
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 12
An old drug with a new future: bendamustine in multiple myeloma 12
Glasdegib for the treatment of acute myeloid leukemia 11
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 11
Isatuximab in multiple myeloma 11
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 11
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 11
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 11
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy 10
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 10
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey 10
The use of ibrutinib before and after allogeneic stem cell transplantation 9
Selinexor in multiple myeloma 9
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 9
An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of chronic lymphocytic leukemia Rai stage 0. 9
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI) 9
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 8
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV 8
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 8
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 8
Le complicanze infettive nella leucemia linfatica cronica 8
Momelotinib in myelofibrosis 8
Zanubrutinib for the treatment of chronic lymphocytic leukemia 8
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 8
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 8
Comparison between the cll-ipi and the barcelona-brno prognostic model: Analysis of 1299 newly diagnosed cases. 7
Enumeration of interleukin-10-positive B cells from peripheral blood of patients with chronic lymphocytic leukemia 7
Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression. 7
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: iLeukemia 7
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 7
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 7
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 7
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 7
Totale 1.559
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.291
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 4 2 0 0 0 1 0 1 0 0
2021/202224 0 2 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/2025158 158 0 0 0 0 0 0 0 0 0 0 0
Totale 2.168